Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral Prednisone 10mg Clear all
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

NCT02921789
View directory record Official record
Conditions
Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Interventions
Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), Tacrolimus Capsules, Methylprednisone, Prednisone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
20
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 9, 2026, 9:36 AM EDT
Terminated Phase 4 Interventional Results available

Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

NCT01676415
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
Prednisone, Topical mometasone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 9, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

NCT00689936
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide and low-dose dexamethasone, Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles, Melphalan, Prednisone and Thalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 9, 2026, 9:36 AM EDT
Terminated Phase 4 Interventional Results available

Reduction in Symptomatic Esophageal Stricture Formation

NCT02039115
View directory record Official record
Conditions
Esophageal Stenosis
Interventions
prednisone, placebo
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Sep 9, 2026, 9:36 AM EDT
Terminated Phase 2 Interventional Results available

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

NCT04918147
View directory record Official record
Conditions
IgG4 Related Disease, IgG4-RD
Interventions
elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 9, 2026, 9:36 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT01714817
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BMS-188667, Mycophenolate mofetil, Prednisone, Placebo matching with BMS-188667
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Long Beach, California • San Leandro, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 9, 2026, 9:36 AM EDT
Recruiting Phase 3 Interventional

Cardiac Sarcoidosis Randomized Trial

NCT03593759
View directory record Official record
Conditions
Cardiac Sarcoidosis, Sarcoidosis
Interventions
Prednisone or Prednisolone, Methotrexate
Drug
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
New Haven, Connecticut • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 9, 2026, 9:36 AM EDT
Completed Phase 1 Interventional

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

NCT00657774
View directory record Official record
Conditions
Asthma
Interventions
FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg, Placebo
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
19
States / cities
Phoenix, Arizona • Anaheim, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2008 · Synced Sep 9, 2026, 9:36 AM EDT
Completed Phase 4 Interventional Results available

Budesonide Inhalation Suspension for Acute Asthma in Children

NCT00393367
View directory record Official record
Conditions
Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions
Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 9, 2026, 9:36 AM EDT
Completed Phase 1 Interventional

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

NCT01634061
View directory record Official record
Conditions
Castration-resistant Prostate Cancer
Interventions
BEZ235, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Los Angeles, California • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 9, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia

NCT02716818
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort®, standard glucocorticoid therapy
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 9, 2026, 9:36 AM EDT
Terminated Phase 2 Interventional

Delayed Release Prednisone in PMR

NCT02702778
View directory record Official record
Conditions
Polymyalgia Rheumatica
Interventions
Delayed-Release (DR) Prednisone, Immediate Release (IR) Prednisone
Drug
Lead sponsor
Dinora, Inc.
Other
Eligibility
50 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Miami, Florida • Mineola, New York • Duncansville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Sep 9, 2026, 9:36 AM EDT
Completed Phase 1 Interventional

Tolerance by Engaging Antigen During Cellular Homeostasis

NCT03504241
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
Interventions
Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept, sirolimus, mycophenolate mofetil, mycophenolate acid, prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 9, 2026, 9:36 AM EDT
Completed Phase 2 Interventional Results available

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

NCT02495077
View directory record Official record
Conditions
Kidney Transplant
Interventions
Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Sep 9, 2026, 9:36 AM EDT
Completed Phase 2 Interventional Results available

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

NCT04028388
View directory record Official record
Conditions
Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
Interventions
Docetaxel in Parenteral Dosage Form, ModraDoc006/r
Drug
Lead sponsor
Modra Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Detroit, Michigan • Las Vegas, Nevada • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 9, 2026, 9:36 AM EDT
Completed Phase 2 Interventional Results available

AZD2171 to Treat Prostate Cancer

NCT00436956
View directory record Official record
Conditions
Prostate Cancer
Interventions
Magnetic Resonance Imaging (DCE-MRI), AZD2171, Prednisone
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 9, 2026, 9:36 AM EDT
Not yet recruiting Phase 4 Interventional

Infliximab for Immune Checkpoint Inhibitor Associated AKI

NCT07683975
View directory record Official record
Conditions
Acute Kidney Injury, Acute Interstitial Nephritis
Interventions
Infliximab, Prednisone, prednisone (oral)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 9, 2026, 9:36 AM EDT
Recruiting Phase 4 Interventional

Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis

NCT07258771
View directory record Official record
Conditions
Ulcerative Colitis Acute
Interventions
Oral Upadacitinib, Intravenous Methylprednisolone, Oral Upadacitinib Placebo, Oral prednisolone Taper, Oral Prednisone - Hospital Dose Steroids
Drug
Lead sponsor
Berinstein, Jeffrey
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 9, 2026, 9:36 AM EDT
Completed Phase 2 Interventional Results available

Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)

NCT01884571
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Basiliximab, Methylprednisolone, Prednisone, Tacrolimus, Mycophenolate mofetil
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 9, 2026, 9:36 AM EDT
Completed Phase 4 Interventional Results available

Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis

NCT02169219
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions
Glucocorticoids, Rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 9, 2026, 9:36 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

NCT02913196
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Apalutamide, Abiraterone acetate, Docetaxel, Prednisone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 9, 2026, 9:36 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT00430677
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Corticosteroids (prednisone or prednisolone), Abatacept, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Sep 9, 2026, 9:36 AM EDT
Completed Phase 1 Interventional

A Study of CC-90011 and Comparators in Participants With Prostate Cancer

NCT04628988
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
CC-90011, Abiraterone, Prednisone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 9, 2026, 9:36 AM EDT
Completed Not applicable Interventional Results available

Oral Steroids in Chronic Rhinosinusitis Without Nasal Polyps

NCT02927834
View directory record Official record
Conditions
Sinusitis
Interventions
6 day Prednisone, Augmentin, 21 day Prednisone
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 9, 2026, 9:36 AM EDT